Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 3/20 | 0.51 |
| ▸ | RAC2 | P15153 | 1/20 | 0.47 |
| ▸ | RAC3 | P60763 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151251 | 0.96 | RAC1 (0.52) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL20678119 | 0.95 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL31121075 | 0.95 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL4146513 | 0.95 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL4591807 | 0.86 | RAC1 (0.52) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL25405582 | 0.85 | RAC1 (0.44) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL25405588 | 0.85 | RAC1 (0.44) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL25402058 | 0.85 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL20678041 | 0.85 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 | |
| SCHEMBL25405308 | 0.85 | RAC1 (0.54) | RAC1RAC2RAC3ADRB2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| EP-1910334-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | Exonhit Therapeutics SA (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | APP, BACE1, IAPP | RAC1 107/4885RAC2 368/4885RAC3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.